1. Home
  2. WYY vs ICCC Comparison

WYY vs ICCC Comparison

Compare WYY & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WidePoint Corporation

WYY

WidePoint Corporation

HOLD

Current Price

$4.65

Market Cap

68.2M

Sector

Technology

ML Signal

HOLD

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

N/A

Current Price

$6.43

Market Cap

55.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WYY
ICCC
Founded
1991
1982
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.2M
55.5M
IPO Year
2005
1995

Fundamental Metrics

Financial Performance
Metric
WYY
ICCC
Price
$4.65
$6.43
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$8.67
N/A
AVG Volume (30 Days)
29.1K
12.2K
Earning Date
03-25-2026
03-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
65.33
EPS
N/A
0.20
Revenue
$150,545,364.00
$26,493,169.00
Revenue This Year
$5.20
N/A
Revenue Next Year
$15.39
N/A
P/E Ratio
N/A
$32.60
Revenue Growth
5.59
51.64
52 Week Low
$2.19
$4.52
52 Week High
$7.55
$7.60

Technical Indicators

Market Signals
Indicator
WYY
ICCC
Relative Strength Index (RSI) 42.80 46.52
Support Level $4.13 $6.20
Resistance Level $4.99 $6.79
Average True Range (ATR) 0.41 0.18
MACD 0.02 0.01
Stochastic Oscillator 13.42 39.26

Price Performance

Historical Comparison
WYY
ICCC

About WYY WidePoint Corporation

WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.

About ICCC ImmuCell Corporation

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

Share on Social Networks: